For investors


Below is a selection of available results:

“Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone”

Bengt Glimelius, et al

Cancer Treatment Review, Volume 98, July 2021 >>

“MYC as a candidate upstream controller involved in TYMS gene expression and 5-FU/folate treatment efficacy in colorectal cancer”

David A. Drubin, et al.

Abstract at ASCO 2021 >>

“Tumoral expression of folate-associated genes is associated with progression-free survival of patients with advanced colorectal cancer”

Yvonne Wettergren, et al.

Poster at AACR 2021 >>

“Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy”

Roger Tell, et al.

Poster at ASCO-GI 2021 >>

“Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin”

Helena Taflin, et al.

Springer Link, October, 2020 >>

“An open-label Phase III study of arfolitixorin vs leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer”

Heinz-Josef Lenz, et al.

Poster at ASCO-GI 2020 >>

“Open-label Phase III Study of Arfolitixorin vs Leucovorin in Modifi ed FOLFOX-6 for First-line Treatment of Metastatic Colorectal Cancer: AGENT”

Stintzing, Sebastian, et al.

Poster at ESMO 2019 >>

“ISO-CC-005; a phase I/II study of arfolitixorin ([6R]-5,10-MTHF) in combination with 5-fluorouracil (5-FU), irinotecan and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer”

Carlsson, Göran, et al.

Poster at ESMO 2018 >>

“Folate gene prediction of treatment response to 5-FU and leucovorin in metastasizing colorectal cancer”

Gustavsson, Bengt, et al.

Poster at ASCO 2018  >>

“A review of the evolution of systemic chemotherapy in the management of colorectal cancer”

Gustavsson, Bengt, et al.

Clinical colorectal cancer 14.1 (2015): 1-10 >>

“Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action”

Danenberg, Peter V., et al.

Critial Reviews in Oncology/Hematology 106 (2016): 118-131 >>

“Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages”

Taflin, Helena, et al.

Cancer chemotherapy and pharmacology 74.6 (2014): 1167-1174 >>


Last updated 07-06-2022